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ABSTRACT
The presence of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and the community is a
serious problem. Accordingly, a comprehensive plan has been implemented in the County of Vejle,
Denmark, to identify colonised and ⁄ or infected individuals and to control the spread of MRSA. Since
2005, all patients and healthcare personnel have been screened for MRSA colonisation, involving
analysis of 300–400 samples daily. To deal with this number of samples, a PCR-based method
customised for high-throughput analysis and a system for fast reporting of MRSA carrier status were
developed. Swab samples were incubated overnight in a selective tryptone soya broth and were
analysed by PCR the following day. Using this strategy, non-colonised individuals were identified
within 24 h, while MRSA-positive samples were analysed further by traditional microbiological
methods to determine the resistance pattern. This is a cost-effective approach, as the greatest expense in
hospitals involves the isolation of patients of unknown MRSA status. The method was evaluated by
testing 2194 clinical samples, with a sensitivity and specificity of 100% and 94%, respectively. The
analytical sensitivity was 97%, with 161 of 166 different MRSA strains and isolates generating positive
results according to PCR analysis. Using four control strains, the inter-assay variation was revealed to be
a maximum of 2.6%, indicating good reproducibility.
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INTRODUCTION
Since the first strains of methicillin-resistant
Staphylococcus aureus (MRSA) were observed dur-
ing the early 1960s [1], the incidence of MRSA has
increased dramatically worldwide, so that MRSA
now constitutes a serious problem in the health-
care sector in many countries [2]. The conse-
quences of an MRSA infection are an increased
length of hospitalisation and increased healthcare
costs [3], and it has also been suggested that
MRSA infections are associated with an increased
mortality rate [4–6]. In contrast to many other
countries in Europe, Denmark had an MRSA
prevalence of <2% throughout the 1980s and
1990s [2]. However, in 2002 the County of Vejle
experienced a large outbreak of MRSA infections
in six hospitals. To prevent the type of endemic
situation observed in, e.g., the UK and Germany
[7,8], a comprehensive control strategy was initi-
ated, involving screening of all healthcare per-
sonnel and all patients upon initial hospitalisation
and at discharge. In addition, the resources of the
infection control department were increased in
order to track and reduce the spread of MRSA, as
contamination of the hospital environment
constitutes a major source of infection [9]. Accord-
ingly, following identification of an MRSA-posi-
tive patient, the patient is isolated and treated,
and a follow-up procedure is started by the
infection control department to ensure that the
patient is cured of MRSA infection. All healthcare
personnel and patients who have had contact
with an MRSA-positive patient are tested for
MRSA. If a known MRSA-positive patient is
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hospitalised, specific precautions are taken. This
intensive infection control strategy required a fast
high-throughput MRSA screening method, and
was therefore not compatible with traditional
microbiological testing using blood agar.
Methicillin resistance in S. aureus is encoded by
the mobile staphylococcal cassette chromosome
mec (SCCmec) element. The SCCmec element
contains the mecA gene, which encodes penicil-
lin-binding protein 2¢ and is responsible for
methicillin resistance [10]. Six different SCCmec
variants have now been identified, each of which
possesses a different sequence and encodes vary-
ing resistance patterns [11–14]. The SCCmec ele-
ment is always integrated specifically in the
S. aureus chromosome by site-specific recombin-
ases at the 3¢ end of an open reading frame (orfX)
located near the replication origin [15,16]. Based
on this knowledge, a PCR detection method was
described in 2004 that targets the orfX of S. aureus
and the right extremity junction of the SCCmec
element, thereby making the method capable of
distinguishing between MRSA and coagulase-
negative staphylococci [17]. Using this strategy
as a starting point, the aim of the present study
was to develop a method for screening a large
number of samples within a short time as part of
the daily workflow of the hospital.
MATERIALS AND METHODS
Reference strains
The reference strains comprised 109 different MRSA strains
obtained from the Statens Serum Institut (SSI; Copenhagen,
Denmark). In addition, 57 clinical MRSA isolates obtained in
the County of Vejle, Denmark were typed by the SSI and
included in the study. The reference strains included most
well-known international strains and the most prevalent
strains in Denmark.
Four strains were used as positive controls: three MRSA
strains typed by the SSI, i.e., 41195 (CC22), 40431 (CC5) and
40126 (CC8-t024), and one clinical isolate (8190) obtained in the
County of Vejle and typed as CC30 by the SSI. The methicillin-
susceptible S. aureus (MSSA) strain ATCC 25923 was used as a
negative control.
Clinical samples
The study included samples collected from 2194 patients
during March ⁄April 2006 at the six hospitals in the County of
Vejle (Kolding, Fredericia, Horsens, Braedstrup, Give and
Vejle Hospitals). The samples were swabs taken from nostril,
throat, perineum, wounds or skin, inserted in Stuart’s trans-
port medium (SSI) and delivered to the Department of Clinical
Microbiology, Vejle Hospital.
Culture conditions and media
The swabs from the nose and throat of each patient were
pooled in a 2.5-mL tryptone soya broth (TSB) containing NaCl
2.5% w ⁄v, aztreonam 10 mg ⁄L and cefoxitin 3 mg ⁄L (SSI) and
incubated overnight at 37C. Swabs from wounds, skin, etc.
were treated individually, but using the same procedure as for
the nose ⁄ throat swabs. Following overnight incubation, 10 lL
of the broth was plated on agar plates containing horse blood
5% v ⁄v (SSI) and incubated at 37C. The remaining broth was
used for DNA extraction and subsequent PCR analysis. The
agar plates were examined after incubation for 1 and 2 days
for typical staphylococcal colonies. On day 2 or 3, potential
S. aureus colonies were identified using the tube coagulase test
and sensitivity to oxacillin (1-lg disk; Rosco, Taastrup,
Denmark) by the agar disk-diffusion method. On day 4 or 5,
coagulase-positive colonies that were resistant to oxacillin
were tested phenotypically for the presence of the mecA gene
using the Slidex MRSA Detection kit (bioMe´rieux, Marcy l’
Etoile, France) and for sensitivity towards 12 selected antibi-
otics. For some randomly chosen false-positive and MRSA-
negative samples (see Results), a sample from the blood agar
plate was stored in meat extract 0.7% v ⁄v agar (SSI) at 4C,
and this was followed by subsequent identification of the
bacteria present in each sample using the Vitek II system
(bioMe´rieux).
DNA extraction
DNA extraction was performed according to the procedure
described by Hagen et al. [18], with adjustments made to
accommodate a high-throughput system using the Biomek FX
pipetting robot (Beckmann, Fullerton, CA, USA). In brief,
950 lL of overnight broth culture was centrifuged at 5100 g for
5 min and the pellet was resuspended in 180 lL of lysis buffer
(Triton X-100 1% v ⁄v, Tween-20 0.5% v ⁄v, 10 mM Tris-HCl,
pH 8.0, 1 mM EDTA). The suspension was heated to 95C for
10 min and then centrifuged at 5100 g (Multifuge 3L; Heraeus,
Osterode, Germany) for 10 min. The supernatant was used for
real-time PCR assays.
Real-time PCR
Multiplex real-time PCR was performed using the primers and
probes described previously [17], except for primer 85 ⁄ 1940,
which is a modification of a primer described by Ito et al. [19].
The sequences and concentrations of all primers and probes
used are shown in Table 1. For each PCR, 3.3 lL of DNA
extract was transferred to 22 lL of PCR mix containing
primers and probes, 2 · TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA), 0.625 U of
AmpliTaq Gold (Applied Biosystems) and TaqMan Exogenous
Internal Positive Control (Applied Biosystems) to monitor any
PCR inhibition. PCR conditions comprised 2 min at 50C
(UNG carryover prevention), followed by 10 min at 95C and
45 cycles of 15 s at 95C and 75 s at 60C, performed on an
ABI 7900 instrument (Applied Biosystems). A sample was
considered to be MRSA-positive when the PCR cycle threshold
(Ct) value was <41, based on receiver operator characteristic
curve calculations generated from the data obtained when the
results of the MRSA PCR were compared with those of the
reference standard of a conventional microbiological culture.
The sensitivity in the receiver operator characteristic curve
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analysis was set at 100% to avoid false-negative samples, and
calculations were performed using the NCSS program (Num-
ber Cruncher Statistical Systems, Kaysville, UT, USA).
Assay verification
The reproducibility of the assay was evaluated by measuring
inter- and intra-assay variation. The coefficient of variation
was assessed in both cases by measuring the Ct values
obtained for independent overnight cultures of four MRSA
control strains, which were processed in the same way as
normal samples. The inter-assay variation was calculated
from 22 independent samples analysed on different days.
The intra-assay variation was based on the average of two
different runs performed with eight duplicate samples. The
amplification efficiency was investigated by measuring
the slope of a standard curve based on a serial dilution of
the four control strains (each dilution was analysed using
three duplicate samples). The PCR amplification efficiency
was calculated using the equation E = 10)(1 ⁄ slope) · 100%,
with an average of two independent experiments being
taken as the final volume. The standard curves were also
used to determine the detection limit of the method, which
denotes the number of CFUs that could be detected
reproducibly by each PCR.
RESULTS
Examination of clinical samples
During this study, 2194 patient samples were
tested for the presence of MRSA by multiplex
PCR and conventional microbiological culture. In
total, 88 samples were MRSA-positive and 1987
samples were MRSA-negative according to both
detection methods. There were no culture-posi-
tive samples that were not detected by PCR, but
119 samples identified as MRSA-positive by the
multiplex PCR were negative according to cul-
ture. Thus, the PCR method had a sensitivity of
100% and a specificity of 94%. The positive
predictive value and negative predictive value
of PCR were 43% and 100%, respectively.
As 5.4% of the 2194 clinical samples were
apparently false-positive in comparison with
culture, 20 of these clinical samples were inves-
tigated microbiologically, with the different spe-
cies in each sample being separated and identified
using the Vitek II instrument. Table 2 shows that
each of the false-positive samples contained
MSSA. Each of the original broths was very
turbid, and had a high content of MSSA, as
identified by culture, coagulase tests and cefoxitin
susceptibility tests (results not shown), despite
the fact that the TSB was designed to be selective
for MRSA. This problem is analysed in more
detail below.
Evaluation of the multiplex PCR using different
bacterial strains and clinical isolates
The analytical sensitivity of the multiplex PCR
was investigated by analysing 166 different
MRSA isolates, of which 161 were PCR-positive
and five were PCR-negative (Table 3), giving an
analytical sensitivity of 97%, which is comparable
to that observed in previous studies [17,18]. No
cross-reactivity was detected with 27 different
microbial species found in 50 ‘MRSA-negative’
clinical samples (Table 4).
Table 1. Primers and probes used
in the multiplex PCR for the detec-
tion of methicillin-resistant Staphylo-
coccus aureus
Primer ⁄probe Sequence (5¢–3¢)
Concentration
in PCR
S. aureus orfX-specific primer GGATCAAACGGCCTGCACA 400 nM
SCCmec-specific primers:
Mecii 574 GTCAAAAATCATGAACCTCATTACTTATG 400 nM
Meciii 519 AATATTTCATATATGTAATTCCTCCACATCTC 400 nM
Meciv 511 CTTCAAATATTATCTCGTAATTTACCTTGTTC 400 nM
85 ⁄ 1940 TCATGAACCTCATTACTTATGATAAGCTTC 600 nM
S. aureus orfX-specific probes:
XsauB5 6-FAM-ACTGCGTTGTAAGACGT-MGB 200 nM
XsauB9 6-FAM-ACTACGTTGTAAGACGTCC-MGB 200 nM
FAM, carboyfluorescein; MGB, minor groove binder.
Table 2. Microbial content of 20 clinical samples that were
false-positive according to PCR






























MSSA, methicillin-susceptible Staphylococcus aureus.
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Characteristics of the multiplex PCR
Four different known MRSA strains were
included in each PCR run as positive controls.
Inter-assay variation was determined, based on
the results of 22 independent samples analysed
during 1 month, and showed a variation in the
Ct values of 1.2–2.6% (Table 5). Likewise, the
intra-assay variation was low (0.8–1.9%), based
on the average of 16 Ct values obtained in two
independent PCR runs.
The PCR efficiency and the detection limit for
each control strain were measured using a serial
dilution of 108–103 CFU ⁄mL from an overnight
culture (the CC8-t024 strain was only tested in the
range 108–106 CFU ⁄mL). The PCR efficiency varied
between 75% and 116%, depending on the strain,
which is acceptable for a multiplex PCR. The
detection limit was 16 CFU ⁄PCR for the CC30
strain, 156 CFU ⁄PCR for the CC22 and CC5 strains,
and 15 600 CFU ⁄PCR for the CC8-t024 strain. The
detection limit of 15 600 CFU ⁄PCR for the CC8-t024
strain was rather high, but was compensated for
by the overnight incubation period of c. 18 h.
As the multiplex PCR appeared to be generat-
ing false-positive reactions with MSSA (see
above), several false-positive samples were anal-
ysed by testing each primer individually in the
PCR (data not shown). Primers 85 ⁄ 1940 and 574
were both found to be associated with false-
positive reactions. Primer 85 ⁄ 1940 was originally
added to the assay to detect a specific CC8 MRSA
strain present in Denmark. None of the primers in
the assay described by Huletsky et al. [17], or the
other candidate primer tested, could detect this
specific CC8 strain (results not shown). Similarly,
primer 574 detects a CC5 MRSA strain that has
been identified in the County of Vejle. Therefore,
omitting either of these two primers would
reduce the number of false-positive reactions,
Table 3. Analytical sensitivity of the multiplex PCR using
previously characterised strains of methicillin-resistant
Staphylococcus aureus (MRSA)
MRSA CC type Number of isolates PCR result
CC1 5 +
CC5 23 +
CC5 (spa type t002) 1 )
CC8 34 +






CC59 (spa type t441) 1 )
CC78 3 +
CC80 10 +
CC80 (spa type t376) 1 )
CC97 2 +
ST152 ⁄ 377 1 +
Singleton 1 +
CC, clonal complex; ST, sequence type.
Table 4. Microbial species found in
50 clinical samples that were nega-
tive for methicillin-resistant Staphy-
lococcus aureus according to the
multiplex PCR
Species No. of isolates Species No. of isolates
Staphylococcus aureus (MSSA) 6 Acinetobacter baumannii (G)) 1
Staphylococcus capitis (CoNS) 1 Gemella morbillorum (G+) 1
Staphylococcus epidermidis (CoNS) 18 Enterococcus faecalis (G+) 12
Staphylococcus haemolyticus (CoNS) 3 Enterococcus faecium (G+) 1
Staphylococcus hominis (CoNS) 1 Enterococcus gallinarum (G+) 1
Streptococcus alactolyticus (G+) 1 Sphingomonas paucimobilis (G)) 1
Streptococcus anginosus (G+) 4 Lactococcus spp. (G+) 8
Streptococcus mutans (G+) 1 Leuconostoc spp. (G+) 3
Streptococcus parasanguinis (G+) 3 Moraxella spp. (G)) 2
Streptococcus pneumoniae (G+) 1 Corynebacterium spp. (G+) 1
Streptococcus salivarius (G+) 13 Candida albicans (yeast) 4
Streptococcus sanguinis (G+) 8 Candida parapsilosis (yeast) 1
Streptococcus thoraltensis (G+) 1 Candida inconspicua (yeast) 1
Streptococcus vestubularis (G+) 1
MSSA, methicillin-susceptible S. aureus; CoNS, coagulase-negative staphylococci; G+, Gram-positive; G), Gram-
negative.
Table 5. Characteristics of the mul-
tiplex PCR with four known strains
of methicillin-resistant Staphylococ-
cus aureus
CC22 CC5 CC30 CC8-t024
Inter-assay variation (CV) 1.2%
(Ct 33.0 ± 0.4)
2.6%
(Ct 34.2 ± 0.9)
2.1%
(Ct 30.6 ± 0.7)
1.8%
(Ct 34.9 ± 0.6)
Intra-assay variation (CV) 1.3%
(Ct 36.6 ± 0.5)
1.9%
(Ct 38.9 ± 0.7)
0.8%
(Ct 34.4 ± 0.3)
0.9%
(Ct 37.7 ± 0.3)
PCR efficiency in the multiplex
reaction
82% 76% 93% 107%
Determination limit (CFU ⁄PCR) 156 156 16 15 600
CC, clonal complex; CV, coefficient of variation; Ct, PCR cycle threshold value.
Ornskov et al. High-throughput PCR-based screening for MRSA 25
 2007 Per Schouenborg, CMI, 14, 22–28
but would increase the risk of false-negative
reactions, which are potentially more serious.
DISCUSSION
MRSA is recognised as one of the most important
nosocomial pathogens, being capable of causing a
number of different clinical manifestations, rang-
ing from mild skin infections to severe and
sometimes life-threatening sepsis [20]. As MRSA
is resistant to many antibiotics, treatment of an
infection is often difficult and prolonged, result-
ing in increased hospitalisation periods and
healthcare costs [3,21,22]. Accordingly, it is
important to control and prevent the spread of
MRSA, and many studies have shown that a
screening and eradication programme is an opti-
mal and cost-efficient solution when compared
with the costs associated with the care of MRSA-
infected patients [23–27]. Recommendations from
Danish Health Authorities suggest that screening,
and eradication after positive identification,
should be the main strategy aimed at preventing
the epidemic spread of MRSA.
The criteria for a successful screening pro-
gramme are that the method used should be fast,
reliable and capable of integration in the daily
workflow of a routine laboratory. In this respect,
the total analysis time for the real-time PCR
method is c. 24 h, which includes an overnight
incubation step, a semi-automated sample prep-
aration step (capable of handling 96 samples
simultaneously), and subsequent real-time PCR.
Other published methods have omitted the over-
night incubation period [18,28], but this approach
resulted in an unacceptably low sensitivity in our
hands. Furthermore, in order to benefit fully from
a shorter analysis time, it would be necessary for
the method to be available for 24 h daily, which
may cause a problem with staffing resources.
Focusing on the cost ⁄ benefit ratio, it seems that
the real-time PCR screening method described in
the present study has the advantages of being
reliable, reasonably fast, easy to implement in the
daily workflow, and able to handle a large
number of samples simultaneously.
The method was evaluated by analysing 2194
clinical samples, and this revealed a sensitivity of
100% and a specificity of 94%. The specificity is
affected by the number of false-positive reactions,
which appear to be caused by a heavy load of
MSSA. One explanation might involve non-mecA-
containing SCC elements that have been reported
to be present in some S. aureus strains [29,30].
Alternatively, the presence of DNA from dead
MRSA in a sample could yield a positive PCR
result and a negative culture result. This could be
the case if the conditions in the TSB were too
stringent, e.g., if the salt concentration was too
high. Primers 574 and 85 ⁄ 1940 were particularly
associated with false-positive results, and a search
of the NCBI databases revealed that both primers
have the possibility of annealing to DNA from
MSSA (data not shown), which may explain why
this and previous studies [17,28,31] have gener-
ated false-positive results using this molecular
detection strategy. However, such false-positive
samples do not lead to inappropriate treatment of
patients, as all PCR-positive samples are further
analysed microbiologically. Only when the
MRSA-positive status is confirmed will medical
treatment be initiated.
The analytical sensitivity of the assay was 97%,
based on an analysis of 166 MRSA strains and
isolates. The five strains that were not identified
have not, to date, been found in the County of
Vejle. Overall, taking into account the variation
reported among SCCmec elements carried by
MRSA strains [13,14,19], the PCR multiplex
method detects a comprehensive selection of
MRSA strains. It will be interesting to determine
whether the method can also be used for detection
of community-acquired MRSA, which may
become an increasing problem in the near future
[32,33].
In addition to sensitivity and specificity, the
reproducibility of a method is also an important
issue. One of the challenges associated with
performing a multiplex PCR is that the primers
may interact and have different optimum anneal-
ing temperatures, which normally requires an
extended optimisation of the PCR conditions [34].
The present study found intra- and inter-assay
variation of <2.6% for the control strains. The
detection limit of the assay was generally slightly
higher than that reported in other studies
[17,18,35], but this was compensated for by the
incubation step included in the assay. It was
concluded that this semi-automated, high-
throughput, real-time PCR-based screening meth-
od for MRSA has good reproducibility, 100%
sensitivity and high specificity. The method has
been implemented in the daily workflow of our
laboratory, where it is currently used to analyse
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300–400 clinical samples daily. More precisely, in
the 6-month period from July to December 2006,
42 112 assays were performed for 24 687 individ-
uals, with 393 assays for 114 individuals being
MRSA-positive.
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